Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how
well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with
stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as
carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether giving carboplatin and paclitaxel together with vorinostat is more effective than
giving carboplatin and paclitaxel together with a placebo in treating non-small cell lung
cancer